These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 12197895)
1. Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. Waterman EA; Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP Clin Exp Immunol; 2002 Sep; 129(3):527-32. PubMed ID: 12197895 [TBL] [Abstract][Full Text] [Related]
2. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977 [TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214 [TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP Clin Exp Immunol; 1998 Dec; 114(3):333-8. PubMed ID: 9844040 [TBL] [Abstract][Full Text] [Related]
5. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311 [TBL] [Abstract][Full Text] [Related]
6. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. Ogg GS; Rod Dunbar P; Romero P; Chen JL; Cerundolo V J Exp Med; 1998 Sep; 188(6):1203-8. PubMed ID: 9743539 [TBL] [Abstract][Full Text] [Related]
7. [Detection of serum autoantibodies to melanocyte and correlation between melanoma antigen recognized by T-cells and vitiligo in children]. Chen JP; Li HP; Jin SH; Zhang JT; Li J Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2107-8, 2111. PubMed ID: 19861278 [TBL] [Abstract][Full Text] [Related]
8. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo. Zhu MC; Liu CG; Wang DX; Zhan Z Genet Mol Res; 2015 Dec; 14(4):16060-73. PubMed ID: 26662399 [TBL] [Abstract][Full Text] [Related]
9. The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo. Austin LM; Boissy RE; Jacobson BS; Smyth JR Clin Immunol Immunopathol; 1992 Aug; 64(2):112-20. PubMed ID: 1643744 [TBL] [Abstract][Full Text] [Related]
10. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo. Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574 [TBL] [Abstract][Full Text] [Related]
11. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423 [TBL] [Abstract][Full Text] [Related]
12. Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. Kroon MW; Kemp EH; Wind BS; Krebbers G; Bos JD; Gawkrodger DJ; Wolkerstorfer A; van der Veen JP; Luiten RM J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1172-5. PubMed ID: 22404127 [TBL] [Abstract][Full Text] [Related]
13. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805 [TBL] [Abstract][Full Text] [Related]
14. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Kemp EH; Waterman EA; Gawkrodger DJ; Watson PF; Weetman AP Br J Dermatol; 1998 Nov; 139(5):798-805. PubMed ID: 9892944 [TBL] [Abstract][Full Text] [Related]
15. Pathogenetic mechanisms of vitiligo in a patient with Sézary syndrome. Knol AC; Quéreux G; Marques-Briand S; Pandolfino MC; Khammari A; Guilloux Y; Dreno B Br J Dermatol; 2005 Dec; 153(6):1207-12. PubMed ID: 16307660 [TBL] [Abstract][Full Text] [Related]
16. Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients. Cui T; Yi X; Guo S; Zhou F; Liu L; Li C; Li K; Gao T Sci Rep; 2016 Nov; 6():36360. PubMed ID: 27821860 [TBL] [Abstract][Full Text] [Related]
17. Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients. Park YK; Kim NS; Hann SK; Im S J Dermatol Sci; 1996 Feb; 11(2):111-20. PubMed ID: 8869031 [TBL] [Abstract][Full Text] [Related]
19. Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo. Kemp EH; Waterman EA; Gawkrodger DJ; Watson PF; Weetman AP Clin Exp Immunol; 2001 Jun; 124(3):509-15. PubMed ID: 11472416 [TBL] [Abstract][Full Text] [Related]
20. Apoptosis of melanocytes in vitiligo results from antibody penetration. Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]